A company that's rallied almost 62,000% since its debut makes for a no-brainer buy in August, while another that had gained more than 60,000% on a year-to-basis is a disaster waiting to happen. For more than three decades, investors have consistently had a next-big-thing technology or trend to captivate their attention and wallets. For instance, artificial intelligence (AI) has been a driving force for Wall Street's major stock indexes for almost three years. But more than one market-driving trend can exist ...

股价波动 - 脑再生科技股价在美东时间6月20日大跌40%，收盘价为38.01美元/股，总市值188亿美元（约合1349.82亿元人民币）[3][4] - 此前公司股价因神经调控芯片通过FDA审批的消息刺激，6月16日盘中最高涨幅超4倍，收盘大涨283%，年内涨幅近500倍[4] - 股价暴跌源于公司未官方证实神经调控芯片消息，且研发投入规模有限与高端芯片技术突破的说法不匹配[5] 公司基本面 - 公司专注于研究、开发和商业化中药，用于治疗神经认知障碍和退化，特别是ADHD和自闭症谱系障碍[7] - 截至2024年6月30日，公司在香港仅有12名员工[8] - 创始人Yat-Gai Au自幼患有ADHD和ASD，公司中医研究基础来自其父的中药配方，但该理论未获中医界广泛认可[8] 财务表现 - 公司尚未从销售任何产品中获得收入，无监管批准、分销能力或专利[10] - 2024财年净利润亏损430.18万美元，连续多年亏损[11] - 研发支出呈下降趋势，2024财年为106.62万美元，低于2023年的158.16万美元[11] 股权结构 - 截至2025年一季度末，创始人Yat-Gai Au持股86.24%，为公司第一大股东[12] - Digital Mobile Venture Ltd持股7.6%，前两大股东合计持股93.84%[12]